# Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

> **NCT00316420** · PHASE1 · COMPLETED · sponsor: **Swedish Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Capecitabine (Xeloda)
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00316420
- **Lead sponsor:** Swedish Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2009-02
- **Final completion:** 2009-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2010-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316420, "Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00316420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*